GZR101
Phase 2Small molecule
GZR101 is one of 51 small molecule programs targeting Efficacy. It is currently in Phase 2.
1
Indications
4
Total Trials
1
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
139 competitors in Efficacy
#DrugCompanyPhaseTrials
1Vabysmo
RochePhase 3
Rayos
RRoxane Laboratories
Phase 3
Paraplatin
AAvyxa
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Lesinurad
EEsperion Therapeutics, Inc.
Phase 3
Insulin 320
Novo NordiskPhase 3
Cetaphil
GGalderma R&D
Phase 3
Veracept
SSebela Women's Health Inc.
Phase 3
Aralen
SanofiPreclinical
Primaquine
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Efficacy1 trial
Adult Subject1 trial
Efficacy and Safety1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GZR101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- GGan and Lee Pharmaceuticals, USA